|
Stevens-Johnson Syndrome Toxic Epidermal Necrolysis Spectrum
|
0.400 |
Biomarker
|
disease |
BEFREE |
Association between HLA-B*5901 and methazolamide-induced Stevens-Johnson syndrome/toxic epidermal necrolysis: a systematic review and meta-analysis.
|
30242287 |
2019 |
|
Stevens-Johnson Syndrome Toxic Epidermal Necrolysis Spectrum
|
0.400 |
Biomarker
|
disease |
BEFREE |
The association with HLA-A*31:01 in patients with SCAR was mainly driven by hypersensitivity syndrome (OR = 12.9; P = 2.1 × 10<sup>-9</sup> ) rather than by Stevens-Johnson syndrome/toxic epidermal necrolysis cases, which showed an association with HLA-B*57:01.
|
31066027 |
2019 |
|
Stevens-Johnson Syndrome Toxic Epidermal Necrolysis Spectrum
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
The association of HLA B*15:02 allele and Stevens-Johnson syndrome/toxic epidermal necrolysis induced by aromatic anticonvulsant drugs in a South Indian population.
|
29076187 |
2018 |
|
Stevens-Johnson Syndrome Toxic Epidermal Necrolysis Spectrum
|
0.400 |
Biomarker
|
disease |
BEFREE |
Among these populations, we observed that HLA-B*1502 is a risk allele for LTG-induced Stevens-Johnson syndrome/toxic epidermal necrolysis (SJS/TEN) in Chinese populations (pooled OR 2.4, 95% CI: 1.20-4.78, P = 0.01), HLA-A*2402 was found to be a significant risk allele for both SJS/TEN (pooled OR 3.50, 95% CI: 1.61-7.59, P = 0.002) and maculopapular eruption (MPE) (pooled OR 2.14, 95% CI: 1.10-4.16, P = 0.03), and HLA-B*3303 was considered to be a protective marker for MPE in Chinese and Korean populations (pooled OR 0.2, 95% CI 0.06-0.64, P = 0.007).
|
30015149 |
2018 |
|
Stevens-Johnson Syndrome Toxic Epidermal Necrolysis Spectrum
|
0.400 |
Biomarker
|
disease |
BEFREE |
Cost-effectiveness analysis of HLA-B*58: 01 genetic testing before initiation of allopurinol therapy to prevent allopurinol-induced Stevens-Johnson syndrome/toxic epidermal necrolysis in a Malaysian population.
|
29176400 |
2018 |
|
Stevens-Johnson Syndrome Toxic Epidermal Necrolysis Spectrum
|
0.400 |
Biomarker
|
disease |
BEFREE |
To determine the cost-effectiveness of universal HLA-B*15:02 screening in preventing carbamazepine-induced Stevens-Johnson syndrome/toxic epidermal necrolysis in an ethnically diverse Malaysian population.
|
28346659 |
2017 |
|
Stevens-Johnson Syndrome Toxic Epidermal Necrolysis Spectrum
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Association of the HLA-B alleles with carbamazepine-induced Stevens-Johnson syndrome/toxic epidermal necrolysis in the Javanese and Sundanese population of Indonesia: the important role of the HLA-B75 serotype.
|
29053440 |
2017 |
|
Stevens-Johnson Syndrome Toxic Epidermal Necrolysis Spectrum
|
0.400 |
Biomarker
|
disease |
BEFREE |
This study demonstrated an association between HLA-B*13:01 and dapsone-induced SCARs including Stevens-Johnson syndrome/toxic epidermal necrolysis and drug reaction with eosinophilia and systemic symptoms in nonleprosy patients.
|
28885988 |
2017 |
|
Stevens-Johnson Syndrome Toxic Epidermal Necrolysis Spectrum
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
The HLA-B*15:02 allele is a risk factor for carbamazepine (CBZ)-induced Stevens-Johnson syndrome/toxic epidermal necrolysis in populations where the allele is prevalent.
|
27020614 |
2016 |
|
Stevens-Johnson Syndrome Toxic Epidermal Necrolysis Spectrum
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Validation of a novel real-time PCR assay for detection of HLA-B*15:02 allele for prevention of carbamazepine - Induced Stevens-Johnson syndrome/Toxic Epidermal Necrolysis in individuals of Asian ancestry.
|
27544047 |
2016 |
|
Stevens-Johnson Syndrome Toxic Epidermal Necrolysis Spectrum
|
0.400 |
Biomarker
|
disease |
BEFREE |
A portion of such reactions is observed to strongly associate with certain human leukocyte antigen (HLA) alleles; one of the strongest associations is the HLA-B*1502 protein with carbamazepine (CBZ)-induced Stevens-Johnson syndrome/toxic epidermal necrolysis (SJS/TEN) - the odds ratio value can even be higher than one thousand.
|
26488421 |
2016 |
|
Stevens-Johnson Syndrome Toxic Epidermal Necrolysis Spectrum
|
0.400 |
Biomarker
|
disease |
BEFREE |
HLA-B*59:01: a marker for Stevens-Johnson syndrome/toxic epidermal necrolysis caused by methazolamide in Han Chinese.
|
25918017 |
2016 |
|
Stevens-Johnson Syndrome Toxic Epidermal Necrolysis Spectrum
|
0.400 |
Biomarker
|
disease |
CTD_human |
Clinical pharmacogenetics implementation consortium guidelines for CYP2C9 and HLA-B genotypes and phenytoin dosing.
|
25099164 |
2014 |
|
Stevens-Johnson Syndrome Toxic Epidermal Necrolysis Spectrum
|
0.400 |
Biomarker
|
disease |
BEFREE |
Patients carrying HLA-B*15:02 are at strongly increased risk for CBZ-induced Stevens-Johnson syndrome/toxic epidermal necrolysis (SJS/TEN) in populations where HLA-B*15:02 is common, but not CBZ-induced hypersensitivity syndrome (HSS) or maculopapular exanthema (MPE).
|
24597466 |
2014 |
|
Stevens-Johnson Syndrome Toxic Epidermal Necrolysis Spectrum
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Association between the HLA-B*15:02 allele and carbamazepine-induced Stevens-Johnson syndrome/toxic epidermal necrolysis in Han individuals of northeastern China.
|
24399721 |
2013 |
|
Stevens-Johnson Syndrome Toxic Epidermal Necrolysis Spectrum
|
0.400 |
Biomarker
|
disease |
BEFREE |
HLA-B*58:01 is a risk factor for allopurinol-induced DRESS and Stevens-Johnson syndrome/toxic epidermal necrolysis in a Portuguese population.
|
23600531 |
2013 |
|
Stevens-Johnson Syndrome Toxic Epidermal Necrolysis Spectrum
|
0.400 |
Biomarker
|
disease |
BEFREE |
Development of a rapid and inexpensive assay for detecting a surrogate genetic polymorphism of HLA-B*58:01: a partially predictive but useful biomarker for allopurinol-related Stevens-Johnson syndrome/toxic epidermal necrolysis in Japanese.
|
22277675 |
2012 |
|
Stevens-Johnson Syndrome Toxic Epidermal Necrolysis Spectrum
|
0.400 |
Biomarker
|
disease |
CTD_human |
Carbamazepine-induced toxic effects and HLA-B*1502 screening in Taiwan.
|
21428768 |
2011 |
|
Stevens-Johnson Syndrome Toxic Epidermal Necrolysis Spectrum
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Expression of HLA-B∗1502 is a marker known to be necessary but not sufficient to predict carbamazepine-induced Stevens-Johnson syndrome/toxic epidermal necrolysis in Han Chinese.
|
21354503 |
2011 |
|
Stevens-Johnson Syndrome Toxic Epidermal Necrolysis Spectrum
|
0.400 |
Biomarker
|
disease |
CTD_human |
Genetic and ethnic risk factors associated with drug hypersensitivity.
|
20485159 |
2010 |
|
Stevens-Johnson Syndrome Toxic Epidermal Necrolysis Spectrum
|
0.400 |
Biomarker
|
disease |
CTD_human |
Association of HLA-B*1502 allele and carbamazepine-induced Stevens-Johnson syndrome among Indians.
|
19915237 |
2010 |
|
Stevens-Johnson Syndrome Toxic Epidermal Necrolysis Spectrum
|
0.400 |
Biomarker
|
disease |
CTD_human |
HLA class I markers in Japanese patients with carbamazepine-induced cutaneous adverse reactions.
|
19694795 |
2010 |
|
Stevens-Johnson Syndrome Toxic Epidermal Necrolysis Spectrum
|
0.400 |
Biomarker
|
disease |
CTD_human |
Common risk allele in aromatic antiepileptic-drug induced Stevens-Johnson syndrome and toxic epidermal necrolysis in Han Chinese.
|
20235791 |
2010 |
|
Stevens-Johnson Syndrome Toxic Epidermal Necrolysis Spectrum
|
0.400 |
Biomarker
|
disease |
BEFREE |
HLA-B*5901 is strongly associated with methazolamide-induced Stevens-Johnson syndrome/toxic epidermal necrolysis.
|
20504258 |
2010 |
|
Stevens-Johnson Syndrome Toxic Epidermal Necrolysis Spectrum
|
0.400 |
Biomarker
|
disease |
CTD_human |
Carbamazepine, HLA-B*1502 and risk of Stevens-Johnson syndrome and toxic epidermal necrolysis: US FDA recommendations.
|
18855540 |
2008 |